Subcutaneous Interval Lengthening of Vedolizumab for Economic Research

NCT06584162 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Diseases

Interventions

DRUG: Vedolizumab Injection

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)